Author:
Baugh Christopher W.,Levine Michael,Cornutt David,Wilson Jason W.,Kwun Richard,Mahan Charles E.,Pollack Charles V.,Marcolini Evie G.,Milling Truman J.,Peacock W. Frank,Rosovsky Rachel P.,Wu Fred,Sarode Ravi,Spyropoulos Alex C.,Villines Todd C.,Woods Timothy D.,McManus John,Williams James
Funder
Portola Pharmaceuticals
Boehringer Ingelheim
American College of Emergency Physicians
Janssen Pharmaceuticals
Janssen Pharma
Portola Pharma
Daiichi-Sankyo
CSL Behring
AstraZeneca
National Heart, Lung, and Blood Institute
Genentech
Abbott
Roche
ACEP
Department of Medicine
Reference65 articles.
1. US emergency department visits for outpatient adverse drug events, 2013-2014;Shehab;JAMA,2016
2. Institute for Safe Medication Practices. QuarterWatch™ (2016 Annual Report) Part II: Oral Anticoagulants—The Nation's Top Risk of Acute Injury from Drugs. July 27, 2017. Available at: https://www.ismp.org/resources/quarterwatchtm-2016-annual-report-part-ii-oral-anticoagulants-nations-top-risk-acute. Accessed November 6, 2019.
3. The epidemiology of venous thromboembolism;Heit;J Thromb Thrombolysis,2016
4. Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?;Moodley;Thromb J,2015
5. Rivaroxaban or aspirin for extended treatment of venous thromboembolism;Weitz;N Engl J Med,2017
Cited by
58 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献